The differential binding and activity of pro 2000 against diverse HIV-1 envelopes

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 2, 2009, Pages 125-129

  Sachdev, Darpun D ^a   Zerhouni Layachi, Bouchra ^a   Ortigoza, Mila ^a   Profy, Albert T ^b   Tuen, Michael ^c   Hioe, Catarina E ^c   Klotman, Mary E ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Indevus Pharmaceuticals   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cervicovaginal lavage; HIV 1; Microbicide; PRO 2000; Recently transmitted viruses

Indexed keywords

GLYCOPROTEIN GP 120; GLYCOPROTEIN R5 120; GLYCOPROTEIN X4 120; PRO 2000; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NAPHTHALENESULFONIC ACID DERIVATIVE; POLYMER;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING ASSAY; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG BINDING; EPITOPE MAPPING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; UTERINE CERVIX CYTOLOGY; VIRUS ENVELOPE; BODY FLUID; DOSE RESPONSE; DRUG EFFECT; METABOLISM; PROTEIN BINDING; TUMOR CELL LINE;

ANTI-HIV AGENTS; BODY FLUIDS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; NAPHTHALENESULFONATES; POLYMERS; PROTEIN BINDING;

EID: 67649173130     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31819f9e31     Document Type: Article

References (32)

1. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS. 2006;20:W13-W23.
2. Taylor BS, Sobieszczyk ME, McCutchan FE, et al. The challenge of HIV-1 subtype diversity. N Engl J Med. 2008;358:1590-1602.
3. Li M, Salazar-Gonzalez JF, Derdeyn CA, et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol. 2006;80:11776-11790.
4. Derdeyn CA, Decker JM, Bibollet-Ruche F, et al. Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science. 2004;303:2019-2022.
5. Overbaugh J, Kreiss J, Poss M, et al. Studies of human immunodeficiency virus type 1 mucosal viral shedding and transmission in Kenya. J Infect Dis. 1999;179(Suppl 3):S401-S404.
6. Chohan B, Lang D, Sagar M, et al. Selection for human immunodeficiency virus type 1 envelope glycosylation variants with shorter V1-V2 loop sequences occurs during transmission of certain genetic subtypes and may impact viral RNA levels. J Virol. 2005;79:6528-6531.
7. Blish CA, Nedellec R, Mandaliya K, et al. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS. 2007;21:693-702.
8. Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A. 2008;105:7552-7557.
9. Dhawan D, Keller M, Klotman ME. Topical microbicides: the time has come. AIDS Read. 2006;16:144-148, 155-158, 161; Discussion 148, 156-157.
10. Schols D, Pauwels R, Desmyter J, et al. Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by T-cells persistently infected with HIV-1. Virology. 1990;175:556-561.
11. Callahan LN, Phelan M, Mallinson M, et al. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions. J Virol. 1991;65:1543-1550.
12. Moulard M, Lortat-Jacob H, Mondor I, et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol. 2000;74:1948-1960.
13. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1977-1987.
14. van de Wijgert JH, Shattock RJ. Vaginal microbicides: moving ahead after an unexpected setback. AIDS. 2007;21:2369-2376.
15. Ramjee G. Microbicides in HIV prevention. HIV Therapy. 2007;1:161-170.
16. Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359:463-472.
17. Dezzutti CS, James VN, Ramos A, et al. In vitro comparison of topical microbicides for prevention of human immunodeficiency virus type 1 transmission. Antimicrob Agents Chemother. 2004;48:3834-3844.
18. Scordi-Bello IA, Mosoian A, He C, et al. Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother. 2005;49:3607-3615.
19. Keller MJ, Zerhouni-Layachi B, Cheshenko N, et al. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis. 2006; 193:27-35.
20. Li M, Gao F, Mascola JR, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005;79: 10108-10125.
21. Perkus ME, Limbach K, Paoletti E. Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol. 1989; 63:3829-3836.
22. Goebel SJ, Johnson GP, Perkus ME, et al. The complete DNA sequence of vaccinia virus. Virology. 1990; 179:247-266, 517-263.
23. Cheshenko N, Keller MJ, MasCasullo V, et al. Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother. 2004;48: 2025-2036.
24. Gorny MK, Williams C, Volsky B, et al. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. J Virol. 2006;80:6865-6872.
25. Turville SG, Aravantinou M, Miller T, et al. Efficacy of Carraguard-based microbicides in vivo despite variable in vitro activity. PLoS ONE. 2008; 3(9):e3162.
26. Tao W, Richards C, Hamer D. Enhancement of HIV infection by cellulose sulfate. AIDS Res Hum Retroviruses. 2008;24:925-929.
27. Fletcher PS, Wallace GS, Mesquita PM, et al. Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants. Retrovirology. 2006;3:46.
28. Veazey RS, Klasse PJ, Schader SM, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature. 2005;438:99-102.
29. Lacey CJ, Wright A, Weber JN, et al. Direct measurement of in-vivo vaginal microbicide levels of PRO 2000 achieved in a human safety study. AIDS. 2006;20:1027-1030.
30. Rusconi S, Moonis M, Merrill DP, et al. Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother. 1996;40:234-236.
31. Krachmarov CP, Honnen WJ, Kayman SC, et al. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J Virol. 2006;80:7127-7135.
32. Liu J, Bartesaghi A, Borgnia MJ, et al. Molecular architecture of native HIV-1 gp120 trimers. Nature. 2008;455:109-113.